a prospective trial in 80 patients randomly allocated to four antimalarial treatment regimens -- mefloquine plus pyrimethamine-sulfadoxine ( 'fansidar ' ) ;
C0700599
pyrimethamine-sulfadoxine
C0060061
fansidar